N-Acryloyl-2-methylpiperidin | 31482-66-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: N-Acryloyl-2-methylpiperidin
• 英文别名: 1-(2-Methylpiperidin-1-yl)prop-2-en-1-one
• CAS: 31482-66-3
• 化学式: C₉H₁₅NO
• 分子量: 153.224
• InChiKey: PZPPNUZQHCOVFS-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.6
• 重原子数：
  11
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.67
• 拓扑面积：
  20.3
• 氢给体数：
  0
• 氢受体数：
  1

文献信息

• [EN] N-[2-({4-[3-(ANILINO)-4-OXO-4,5,6,7-TETRAHYDRO-1H-PYRROLO[3,2-C]PYRIDIN-2-YL]PYRIDIN-3-YL)OXY)ETHYL]PROP-2-ENAMIDE DERIVATIVES AND SIMILAR COMPOUNDS AS EGFR INHIBITORS FOR THE TREATMENT OF CANCER<br/>[FR] DÉRIVÉS DE N-[2-({4-[3-(ANILINO)-4-OXO-4,5,6,7-TÉTRAHYDRO-1H-PYRROLO[3,2-C]PYRIDIN-2-YL]PYRIDIN-3-YL)OXY)ÉTHYL]PROP-2-ÉNAMIDE ET COMPOSÉS SIMILAIRES UTILISÉS EN TANT QU'INHIBITEURS D'EGFR POUR LE TRAITEMENT DU CANCER
  申请人：BAYER AG

  公开号：WO2022101184A1

  公开（公告）日：2022-05-19

  The present invention relates to compounds of formula (I) as EGFR inhibitors for the treatment of cancer. An exemplary compound is e.g. N-[2-(4-[3-(3-chloro-2-methoxyanilino)-4-oxo-4,5,6,7-tetrahydro-1 H-pyrrolo[3,2-c]pyridin-2- yl]pyridin-3-yl}oxy)ethyl]prop-2-enamide (example 1).

  本发明涉及式（I）的化合物，作为EGFR抑制剂用于癌症治疗。一个典型的化合物是N-[2-(4-[3-(3-氯-2-甲氧基苯胺基)-4-氧代-4,5,6,7-四氢-1H-吡咯[3,2-c]吡啶-2-基]吡啶-3-基}氧基)乙基]丙烯酰胺（示例1）。
• Composition and preparation of hydrogel nanocomposites with improved mechanical properties and use thereof.
  申请人：Université de Liège

  公开号：EP2607404A1

  公开（公告）日：2013-06-26

  Composition, preparation method and use of a hydrogel nanocomposite (HNC) material, containing one or more water soluble monomers (A), a water swelling clay mineral (B) with a high solubility in water, and water itself(C), with added components resulting in a high compression modulus of the HNC material.

  一种水凝胶纳米复合材料（HNC）的组成、制备方法和用途，该材料含有一种或多种水溶性单体（A）、一种在水中溶解度高的水膨胀粘土矿物（B）以及水本身（C），添加的成分可使 HNC 材料具有较高的压缩模量。
• 4,6,7-TRISUBSTITUTED 1,2-DIHYDROPYRROL[3,4-C]PYRIDIN/PYRIMIDIN-3-ONE DERIVATIVE AND USE
  申请人：Shanghai Haiyan Pharmaceutical Technology Co., Ltd.

  公开号：EP3689871A1

  公开（公告）日：2020-08-05

  The present disclosure relates to 4,6,7-trisubstituted 1,2-dihydropyrrolo[3,4-c]pyridin/pyrimidin-3-one derivatives, and their preparations and medicinal use. Specifically, the present disclosure discloses a compound of formula (I) or a pharmaceutically acceptable salt, stereoisomer, solvate or prodrug thereof, and a preparation method and use thereof, wherein the definition of each group is as described in the specification and claims.

  本公开涉及4,6,7-三取代的1,2-二氢吡咯并[3,4-c]吡啶/嘧啶-3-酮衍生物及其制剂和药用。具体地说，本公开公开了式(I)化合物或其药学上可接受的盐、立体异构体、溶媒或原药及其制备方法和用途，其中各组的定义如说明书和权利要求书中所述。
• Substituted pyrrolo[3,2-d]pyrimidines and pyrazolo[4,3-d]pyrimidines as tyrosine kinase inhibitors
  申请人：Shenzhen TargetRx, Inc.

  公开号：US11186578B2

  公开（公告）日：2021-11-30

  A fused bicyclic compound having an effect in inhibition of the activity of a tyrosine kinase, and preparation, compositions, and uses thereof are disclosed. In particular, compounds of formula (I) and (II), or a pharmaceutically acceptable salt, a stereoisomer, a solvate, a hydrate, a polymorph, a prodrug or an isotopic variation thereof, as well as a pharmaceutical composition including the same are disclosed. Compounds disclosed herein are substituted pyrrolo[3,2-d]pyrimidines and are selective irreversible inhibitors of Bruton's tyrosine kinase. The described compounds can therefore be used for preventing or treating diseases such as inflammation, autoimmune diseases (such as rheumatoid arthritis), xenogeneic immune diseases and cancers.

  本发明公开了一种具有抑制酪氨酸激酶活性作用的融合双环化合物及其制备方法、组合物和用途。特别是公开了式(I)和(II)化合物，或其药学上可接受的盐、立体异构体、溶解物、水合物、多晶型物、原药或同位素变体，以及包括其在内的药物组合物。本文公开的化合物是取代的吡咯并[3,2-d]嘧啶，是布鲁顿酪氨酸激酶的选择性不可逆抑制剂。因此，所述化合物可用于预防或治疗炎症、自身免疫性疾病（如类风湿性关节炎）、异种免疫性疾病和癌症等疾病。
• PYRROLO[2,3-D]PYRIMIDINYL, PYRROLO[2,3-B]PYRAZINYL AND PYRROLO[2,3-D]PYRIDINYL ACRYLAMIDES
  申请人：Pfizer Inc.

  公开号：EP3077395B1

  公开（公告）日：2017-11-15